Balanced news tone
News Sentiment
CRDL sentiment intelligence
Cardiol Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
29 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+3.1% over one week, -17.3% over four weeks, trend inactive, and near fair-value range.
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
3.1%
Price confirming higher
Trend fit
Trend inactive
-17.3% over four weeks
Fair value
-18.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
23
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 03:20
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Institutional Confidence
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 02:43
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Risk Assessment: Volatility, Financial Risk & Investment Risk
- Tone
- Negative 5/100
- Event
- Market update
- Published
- 19 Jun 2026 02:41
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Financial Health: Profitability & Balance Sheet Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 02:13
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 23:39
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Valuation: PE, PB & Fair Value Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 23:34
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:31
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 12:13
- Source
- TradingKey
TradingKey
Direct company coverage
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jun 2026 11:22
- Source
- TradingKey
ChartMill
Direct company coverage
CRDL News | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 00:13
- Source
- ChartMill
simplywall.st
Direct company coverage
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 15 May 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Cardiol Therapeutics expands Phase III trial to 25 sites
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Investing.com
Stock Titan
Direct company coverage
Cardiol plans 7 more U.S. sites for heart-drug trial at 75% enrollment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Stock Titan
TMX Newsfile
Direct company coverage
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Apr 2026 07:00
- Source
- TMX Newsfile
TMX Newsfile
Direct company coverage
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 23 Jan 2026 08:00
- Source
- TMX Newsfile
Market source
Direct company coverage
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- Market source
Investing.com
Direct company coverage
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 02 Dec 2025 08:00
- Source
- Investing.com
Investing News Network
Direct company coverage
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Investing News Network
thedeepdive.ca
Direct company coverage
A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Aug 2025 07:00
- Source
- thedeepdive.ca
Investing News Network
Direct company coverage
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Aug 2025 07:00
- Source
- Investing News Network
GuruFocus
Direct company coverage
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | CRDL Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 May 2025 07:00
- Source
- GuruFocus
Investing News Network
Direct company coverage
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Oct 2024 07:00
- Source
- Investing News Network
Investing News Network
Direct company coverage
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2024 07:00
- Source
- Investing News Network
Investing News Network
Direct company coverage
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2024 16:52
- Source
- Investing News Network
Investing News Network
Direct company coverage
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jan 2024 08:00
- Source
- Investing News Network
TMX Newsfile
Direct company coverage
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2022 07:00
- Source
- TMX Newsfile
MarketBeat
Direct company coverage
Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $CRDL
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Aug 2021 02:08
- Source
- MarketBeat
Market source
Direct company coverage
Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Aug 2021 07:00
- Source
- Market source